The healthcare
agenda is changing, and business competition is increasing. To meet
these challenges, Novo Nordisk’s future drug development ambitions
call for a higher innovation threshold, expansion into other therapy
areas and more external partnerships.
The conversation
between a person with diabetes and their doctor usually focuses on
blood glucose control. But living with diabetes comes with a number
of life-threatening risks, including cardiovascular events and
severe hypoglycaemic episodes – risks that novel diabetes treatments
can now reduce. And so the conversation is changing.
The
underlying cause of obesity is an energy imbalance between calories
consumed and calories expended. But this is only part of the story.
The science behind obesity is complex – and maintaining weight loss is
not easy.
